Synthetic Lethal Interactions in Cancer Therapy.
Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as "synthetic lethality". Nowadays, synthetic lethality has become a widely used anti-cancer strategy.



We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016.



Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.
Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China.
Xinwei
X
Geng
Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China.
Xiaohui
X
Wang
Department of Respiratory Medicine, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, Jinhua, China.
Dan
D
Zhu
Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China.
Songmin
S
Ying
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D055808:Drug Discovery; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015398:Signal Transduction
D000970:Antineoplastic Agents
PARP inhibitors; Synthetic lethality; cancer therapy; drug resistance; signaling pathways; targeted therapy